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Southern Sudan is one of the areas in eastern Africa 
most affected by visceral leishmaniasis (kala-azar), but lack 
of security and funds has hampered control. Since 2005, 
the return of stability has opened up new opportunities to 
expand existing interventions and introduce new ones. 
V
isceral leishmaniasis (kala-azar) is a deadly disease 
caused by the Leishmania protozoan parasite and 
transmitted through the bite of sandﬂ  ies. Without prompt 
appropriate treatment, as many as 95% of kala-azar patients 
die, resulting in at least 50,000 deaths per year worldwide 
(1). Each death equates to a loss of 34 disability-adjusted 
life years (2). Continuous and large-scale control of kala-
azar in the 2 foci of Southern Sudan has been hampered 
by war and instability. However, after the Comprehensive 
Peace Agreement between Northern and Southern Sudan 
was signed on January 9, 2005, the return of relative stabil-
ity to Southern Sudan is now opening up new opportunities 
for supporting and improving healthcare delivery.  To raise 
international awareness of kala-azar in Southern Sudan, we 
reviewed the available data and interventions and report the 
current status and plans for control of kala-azar. 
The Review
Kala-azar occurs in 2 foci (Figure 1) and is caused by 
L. donovani. In the northern focus (Upper Nile, Jonglei, and 
Unity states), Phlebotomus orientalis is the vector; in the 
southern focus (parts of Eastern Equatoria state), P. martini 
is the vector (3,4). Although studies in eastern Sudan have 
found domestic animals infected with the parasite (5,6), 
whether these animals play a role as disease reservoirs has 
not yet been proven; thus, transmission is still thought to be 
anthroponotic.
The disease was ﬁ  rst reported from Southern Sudan in 
1904, and the ﬁ  rst epidemic was documented in 1940 with 
a death rate of 80% (7). Beginning in 1984, an epidemic 
(unrecognized until 1988) devastated the western part of 
Upper Nile state, ultimately causing ≈100,000 deaths in a 
population of 280,000 over a 10-year period (3).
Passive case-detection data on kala-azar in Southern 
Sudan, collected by the World Health Organization (WHO) 
since 1989, indicate a cyclical pattern of kala-azar with con-
siderable variation in the caseload from year to year (Figure 
2). The dynamics presented in Figure 2 also suggest that 
Southern Sudan is currently between epidemics and pro-
vide a warning that cases may rise dramatically in coming 
years. In 2006, a total of 1,117 cases were reported, 65.4% 
of which were primary cases; the remainder were either 
relapses or cases of post–kala-azar dermal leishmaniasis. 
From January through June 2007, a total of 492 cases were 
reported, of which 88.2% were primary cases. The 5 loca-
tions accounting for 74.2% of the primary cases in 2007 
were Malakal (n = 83), Ulang (n = 72), Nasir (n = 63), and 
Kiechkuon (n = 25) in Upper Nile state and Lankien (n = 
79) in northern Jonglei state. Since 2002, the case-fatality 
rate recorded at healthcare facilities has been 4%–6%.
These data likely underestimate the actual number of 
cases because healthcare providers do not always provide 
complete reports and many kala-azar patients never visit 
healthcare facilities. Epidemiologic modeling of data from 
Upper Nile state estimated that those who visited health-
care facilities from October 1998 through May 2002 repre-
sented only 55% of cases and that 91% of kala-azar deaths 
were undetected (8). Health coverage is so minimal that 
some patients must walk for several days to access even the 
most basic healthcare services. 
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Figure 1. Map of Southern Sudan showing the 2 foci of visceral 
leishmaniasis. Shaded areas represent those counties where 
primary cases were reported from January through June 2007. 
Insert shows location of Sudan in Africa. (Adapted from World 
Health Organization, Southern Sudan Health Update, July–August 
2007.)Kala-azar, Southern Sudan
Despite the availability of different rapid diagnostic 
tests, most facilities used clinical diagnosis alone until re-
cently. Only a few had the supplies and equipment to conﬁ  rm 
suspected cases through microscopic examination of lymph 
node aspirate, which has a sensitivity of only 53%–65% 
(1). Nongovernment healthcare providers and Government 
of Southern Sudan–administered healthcare facilities thus 
had to conﬁ  rm suspected kala-azar by direct agglutination 
test before they could receive a supply of the ﬁ  rst-line treat-
ment—sodium stibogluconate—from WHO through Phar-
maciens sans Frontières. The use of the direct agglutination 
tests was required because of concerns about the sensitivity 
and speciﬁ  city of the rK39 dipsticks in East Africa; a recent 
study suggests that these concerns were well founded (9). 
Also, many facilities that had received dipsticks were not 
using them. Until 2004, many healthcare facilities did not 
have the equipment or skills to conduct direct agglutination 
tests, and blood samples had to be sent to Kenya for analysis, 
which often led to treatment delays as long as 18 days. Now 
some healthcare facilities can analyze these samples inter-
nally and start treatment within 24 hours.
Conﬁ  rmed cases are treated with sodium stiboglucon-
ate at a dose of 20 mg/kg/day for 30 days. Recently, be-
cause of an increasing number of patients in Upper Nile 
state who were nonresponsive to sodium stibogluconate, 
Médicins sans Frontières tested a combination of sodium 
stibogluconate and paromomycin, which would reduce 
treatment duration (from 30 to 17 days) and cost. Patient 
survival and initial cure rates were better than those for pa-
tients who received sodium stibogluconate monotherapy 
(10). However, completion of multicountry phase III trials 
being conducted by the Drugs for Neglected Diseases Ini-
tiative (www.dndi.org) is eagerly awaited before the com-
bination can be considered as an alternative. Amphotericin 
B, a second-line drug for treatment of kala-azar, is not yet 
available in Southern Sudan’s facilities except in those run 
by Médicins sans Frontières.
Much remains unknown about the epidemiology of 
kala-azar in Southern Sudan (11). In the absence of de-
tailed information on risk factors (cultural, demographic, 
epidemiologic, clinical, and geographic), use of long-
lasting insecticide-treated nets seems a suitable method of 
prevention. Results from studies in North Sudan showed 
that insecticide-treated nets provided 27% protection from 
kala-azar (12). Whether similar protection can be achieved 
in Southern Sudan’s disease-endemic areas requires conﬁ  r-
mation because effectiveness is dependent on human and 
vector behavior (13).
The return of stability to Southern Sudan has opened 
up new challenges and opportunities for kala-azar control. 
Large-scale population movement of susceptible or in-
fected populations into kala-azar–endemic or –nonendemic 
areas respectively, poses a major epidemic risk. The health-
care systems are weak and rely on support from faith-based 
and nongovernment organizations, which need to be coor-
dinated to ensure consistency in diagnosis, treatment, and 
prevention. As health infrastructure and human resources 
are being built up, kala-azar will need to be addressed as 
an integral part of multifunctional healthcare delivery by 
government staff, but this requires training and the provi-
sion of essential supplies.
Kala-azar falls under the mandate of the Director Gen-
eral of Preventive Medicine within the Ministry of Health–
Government of Southern Sudan. The Ministry of Health, 
with support from WHO and in conjunction with nongov-
ernment organizations working on kala-azar, has embarked 
on a number of activities to strengthen case-management. 
Laboratory technicians in most referral facilities have now 
been trained on direct agglutination testing; case-manage-
ment guidelines have been updated; the essential drugs list 
is being reviewed and expanded to include alternatives for 
second-line treatment; and rK39 dipsticks are being distrib-
uted to peripheral health facilities to complement clinical 
diagnosis. With the revision of diagnosis and treatment 
guidelines, facilities are now able to obtain sodium stibog-
luconate by providing Pharmaciens sans Frontières with a 
positive rapid diagnostic test result, but they are encouraged 
to also take a blood sample for direct agglutination testing, 
as this is still considered more reliable (8). Meanwhile, the 
UK-based Malaria Consortium is providing long-lasting 
insecticide-treated nets to areas in Jonglei and Eastern 
Equatoria, where malaria and kala-azar are endemic.
Conclusions
A strong presence of international donors and the 
Southern Sudan government’s desire to quickly recon-
struct the healthcare sector provide ample opportunity to 
reduce the incidence of kala-azar. However, this goal can 
be achieved only with the necessary resources.
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Figure 2. Total annual number of kala-azar cases in Southern 
Sudan reported to the World Health Organization, 1989–2006.Acknowledgments
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